AWARD
A -- COVID-19: HHS-NIH-NIAID-BAA2020-1: Research Area 004, Development of Therapeutics Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
- Notice Date
- 8/31/2020 6:11:45 AM
- Notice Type
- Award Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIAID-BAA2020-1
- Archive Date
- 09/30/2020
- Point of Contact
- Swee L. Teo, Phone: 2406695173
- E-Mail Address
-
teosl@niaid.nih.gov
(teosl@niaid.nih.gov)
- Award Number
- 75N93020C00055
- Award Date
- 08/31/2020
- Awardee
- BIOCRYST PHARMACEUTICALS, INC. Durham NC USA
- Award Amount
- 43907603.00
- Description
- COVID-19: This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award. This contract is to manufacture and evaluate the safety, efficacy and tolerability of galidesivir a broad spectrum, antiviral therapeutic.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/74724beee8e645a0ba1b68b8612d266b/view)
- Record
- SN05779424-F 20200902/200831230143 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |